TEVOGEN BIO HOLDINGS INC. - COMMON STOCK

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

07 Jun 2024 14:32:04 By Nasdaq GlobeNewswire

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

06 Jun 2024 17:14:31 By Nasdaq GlobeNewswire

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

06 Jun 2024 14:52:26 By Nasdaq GlobeNewswire

Tevogen Bio Reports First Quarter 2024 Financial Results

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

16 May 2024 13:00:00 By Nasdaq GlobeNewswire

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

10 May 2024 16:40:49 By Nasdaq GlobeNewswire

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

01 May 2024 07:05:00 By Nasdaq GlobeNewswire

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

26 Apr 2024 08:23:59 By Nasdaq GlobeNewswire

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

11 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

03 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

28 Mar 2024 07:05:00 By Nasdaq GlobeNewswire